IRIDEX has introduced a new formulated non-invasive, MicroPulse technology-based glaucoma procedure. During the recent American Society of Cataract and Refractive Surgery (ASCRS), IRIDEX launched the new tissue-sparing, repeatable glaucoma therapy known as MicroPulse Laser Trabeculoplasty (MLT).
Irreversible blindness in adults is caused by Glaucoma, which affects over 4 M people in the US and 60 M individuals globally.
IRIDEX President and CEO, Dr. Dominik Beck said that IRIDEX debuted MLT in infrared laser platforms. With rapid emergence of technological advancements, MLT has been introduced with the IRIDEX green laser system, IQ 532. It is the most-preferred, versatile laser that serves a wide range of ophthalmologists. The IQ 532’s unique feature is to ensure tissue-sparing repeatable therapies for individuals with glaucoma and retinal disease. In addition, it presents ophthalmologists with a high return on investment.
Gossage Eye Institute’s medical director, David Gossage, M.D., said that the IQ 532 based on MicroPulse module is more versatile and effective than other lasers involved in glaucoma treatment. It is also effective for other associated diseases such as retinal tears, diabetic macular edema, and proliferative diabetic retinopathy. For more effective results, the IQ 532 system can be equipped with the MicroPulse module.
Laser pulses are generated at short durations in MLT. This enables therapeutic response wherein the intra-ocular pressure of a glaucoma patient is reduced without causing any thermal damage.
Source: http://www.iridex.com/